Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23135331 | 0.89 | KDM4E (0.40) | HTR1AADRA1BKDM4EDRD2DRD3 | |
| SCHEMBL21107507 | 0.87 | KDM4E (0.43) | HTR1AADRA1BKDM4EDRD2DRD3 | |
| SCHEMBL25622445 | 0.81 | OPRM1 (0.40) | HTR1AADRA1BKDM4EDRD2DRD3 | |
| SCHEMBL24589644 | 0.80 | KDM4E (0.40) | KDM4EDRD2DRD3SIGMAR1CYP1A2 | |
| SCHEMBL18820461 | 0.79 | TSHR (0.46) | DRD2DRD3CYP1A2CYP2D6 | |
| SCHEMBL255945 | 0.78 | TSHR (0.42) | HTR1AADRA1BKDM4ECYP2D6 | |
| SCHEMBL23135328 | 0.77 | DRD2 (0.49) | DRD2DRD3SIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL24847793 | 0.77 | KDM4E (0.41) | HTR1AADRA1BKDM4EDRD2DRD3 | |
| SCHEMBL22958640 | 0.77 | OPRM1 (0.40) | KDM4EDRD2DRD3CYP2D6 | |
| SCHEMBL2745438 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | OPRM1, OPRL1, OPRD1 | HTR1A 226/4885ADRA1B 113/4885KDM4E 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.